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Background: Renal-transplant recipients (RTR) have an increased risk of developing non-
melanoma-skin-cancer, mainly squamous cell carcinoma (cSCC). Two genes (TMC/EVER), mutat-
ed in epidermodysplasia verruciformis patients (EV) with an increased risk of cSCC development, 
contain numerous single-nucleotide-polymorphisms (SNP). 
Aim: To evaluate the effect of SNPs in both TMC/EVER genes on different susceptibility of RTRs 
to cSCC.  
Method: We determined the occurrence of cSCC in 105 RTR who were transplanted at least 7 
years ago and investigated the frequency of 26 SNPs within both TMC/EVER genes in severely-
affected (n=16) as well as in not-affected RTR (n=25).  
Results: Our data did not indicate a significant association between any SNP genotype and risk of 
cSCC development in RTR.  
Conclusion: To clarify the correlation between SNPs in TMC and cSCC development in RTR, inte-
grated investigations of large cohorts including both RTR and immunocompetent individuals with 






Kidney transplantation is the preferred modality of renal replacement therapy for many patient 
with end stage renal disease. As short-term patient and allograft survival are excellent nowadays, 
improvement of long-term morbidity and mortality due to malignancies have emerged as key 
goals. Renal transplant recipients (RTR) have at least a 3 to 4-fold increased risk of developing 
cutaneous cancer after transplantation compared to the general population [1]. The most com-
mon cancer in RTR is non-melanoma skin cancer (NMSC). While the usual incidence ratio of 
SCC:BCC is 1:4 in the immunocompetent population, this ratio is reversed in transplant recipi-
ents. The risk of developing cutaneous squamous cell cancer (cSCC) is estimated to be 65-fold 
higher than for the general population [2]. Therefore more than 36% of all transplanted and im-
munosuppressed patients develop at least one NMSC after transplantation [3,4]. UV irradiation, 
type and duration of immunosuppression, as well as age at transplantation and time period after 
transplantation consist the main risk factors for the development of cSCCs. Furthermore, fair skin 
as well as history of prior skin cancer and actinic keratoses are known to increase the risk of 
NMSC emergence [5,6] but do not cover the individual risk. Therefore all RTR are yearly supplied 
with follow-up examinations. Identification of a genetic risk factor might help to estimate the 
individual risk and to establish an individual monitoring resulting in lower healthcare costs.  
Epidermodysplasia verruciformis (EV) is a rare autosomal recessive disorder leading to an in-
creased susceptibility to persistent infections by cutaneous β-human papillomaviruses (β-HPV) 
[7]. Patients with EV develop disseminated cutaneous wart-like lesions and have an increased 
risk of developing cSCC in sun exposed skin areas, which is comparable to the risk of skin cancer 
development in RTR. In 2002, homozygous nonsense and frameshift mutations in the 
TMC6/EVER1 and TMC6/EVER2 genes have been identified in patients with EV [8] and could be 
confirmed in about 75% of patients. These loss-of-function mutations result in an increased sus-
ceptibility to infections by specific HPVs of the genus β, mainly HPV5 and 8 [8]. Both TMC/EVER 
genes contain numerous single nucleotide polymorphisms (SNP), most of them leading to mis-
sense mutations. Their relevance on cancer development has been discussed recently [9-11].  
Likewise another SNP (rs1042522) in the TP53 gene (c. 215CCC>CGC; p.Pro72Arg) at codon 72 
has been controversially discussed to be associated with cancer development [12-16]. This alter-
ation possibly increases the susceptibility of the TP53 protein to degradation mediated by E6 of 
HPVs [17,18]. An important hint for the involvement of SNP rs1042522 in non-melanoma skin 
cancer development is its homozygosity in a considerable number of EV patients [19]. Further-
more this SNP was significantly associated with NMSC development in RTRs [20].  
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The objective of our pilot study was to evaluate a direct correlation of SNPs within TMC6/EVER1 
and TMC8/EVER2 as well as to prove influences of rs1042522 in TP53 on an increased risk of 
cSCC development in RTR. 
 
Materials and Methods 
Study population 
The study was approved by the Ethics Committee of Basel, Switzerland (EK11/10) and informed 
consent was given by all participants. The procedures were in accordance with the Helsinki Dec-
laration. 
105 RTR of Central European origin who had been transplanted and followed after transplanta-
tion at one center (University Hospital Basel, Switzerland) at least 7 years ago were included in 
the study; data were collected from patient records. Patients were classified according to the 
number of previous and current NMSC and warts as well as type of medically induced immuno-
suppression, Fitzpatrick skin type, and UV exposition. Patients with a history of cancer other than 
cSCC or basal cell carcinoma (BCC) were not included in the study. Patients were grouped into 
severely affected (multiple (≥3) cSCC, group 1, n=16), moderately affected (development of one 
or two cSCC or no cSCC but BCC and/or precancerous lesions, group 2, n=64), and not-affected 
patients (no cSCC, no warts, no precancerous lesions, group 3, n=25). The anonymous control 
group (n = 113) included non-transplanted individuals from the general Central European popula-
tion without known increased risk of cSCC. The mean age at transplantation was 42 years 
(group1), 46 years (group 2) and 40 years (group 3). The male:female ratio was 4:1 (group 1), 
1.3:1 (group 2), and 1.4:1 (group 3).  
All patients have received immunosuppressive treatment with cyclosporine, azathioprine, pred-
nisone, rapamycin, mycophenolatmophetil, and tacrolimus. On most of them the drugs were 
administered in combined therapy (e.g. cyclosporine/prednisone, azathioprine/prednisone, cy-
closporine/mycophenolatemophetil, rapamycin/mycophenolatemophetil). Comparison of medi-
cation between the patients showed a comparable immunosuppressive treatment for all groups. 
In only one patient immunosuppressive treatment was stopped because of severe progression of 
cancers with brain invasion and skin metastasis. 
 
DNA preparation and SNP analysis 
Genomic DNA was extracted from peripheral blood lymphocytes following standard salting out 
procedure. PCR (Qiagen, Valencia, CA, USA) was performed by means of primers amplifying the 
entire coding sequences of the TMC6 and TMC8 genes as well as exon intron boundaries. Primer 
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sequences were kindly imparted by G. Orth, France. In order to test our hypothesis in a pilot 
study, we focused on comparing genotypes of RTR, who were severely affected by multiple cSCCs 
and precancerous lesions  (group 1) and patients not affected by cSCC, precancerous lesions or 
warts (group 3). In a first attempt to detect SNPs influencing cSCC development in RTRs purified 
PCR products (NucleoSpin Extract II, Machery-Nagel) of individuals in group 1 (n = 5) and group 3 
(n = 4) were subjected to bi-directional sequencing using the Big-Dye terminator kit (v 3.1) and 
ABI Prism 377 sequencer (Applied Biosystems, Foster City, CA). Distinguished non-synonymous 
SNPs or SNPs possibly affecting the splice sites were screened in all RTR patients of both groups. 
Screening of TMC/EVER SNPs was carried out either by TaqMan® SNP Genotyping Assay (Applied 
Biosystems, Carlsbad, CA) according to the manufacturers instruction or by restriction fragment 
length polymorphism analysis (RFLP). For RFLP, PCR products spanning the region of interest 
were digested with site-specific enzyme (New England Biolabs) according to manufacturer’s in-
structions (Table 1) (primer sequences are available on request). TP53 SNP rs1042522 was char-
acterized by RFLP after digestion of the PCR product with FauI (New England Biolabs). 
 
Statistical Analysis 
Data analysis of the genotypes was assessed using the statistical program R (http://www.r-
project.org/). In case if the presence of three different genotypes for a specific SNP the signifi-
cance was calculated by the Cochran-Armitage test (CATT) and logistic regression. In case of only 
two different genotypes for a specific SNP the Fisher test (FT) was applied. All significances were 
calculated using the additive model. 
 
Results 
In our study collective 16 patients (15.2%) were severely affected by cSCC (group 1). Patients in 
this group (n = 10/62.5%) suffered from multiple cSCC as well as from multiple precancerous le-
sions, which developed between 3 and 24 years after transplantation (median age at first cSCC 
58±14 years). Four patients (25%) were afflicted with 4 to 8 cSCC additional to precancerous 
lesions and two patients (12.5%) developed three cSCC combined with multiple precancerous 
lesions at an early time point after transplantation (6 and 9 years). Group 2 consisted of 64 pa-
tients (61.0%), who developed only one, two, or no cSCC but one precancerous lesion or BCC at 
least. Group 3 consisted of 25 patients (23.8%) who have never developed cSCC, BCC, or precan-
cerous lesions (median age at examination 54±12 years). 
Genotypes in both TMC/EVER genes were investigated in patient groups, which differed most 
strongly regarding development of cSCC (group 1 and 3). Sequence analysis of all exons as well as 
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of exon-intron boundaries of both TMC/EVER genes revealed 23 SNPs (TMC6/EVER1) and 27 
SNPs (TMC8/EVER2) present heterozygously or homozygously. One is a novel variant (c.1766G>A, 
p.(Arg586His)) in the exon 14 of TMC8/EVER2. Comparison of the frequency of 26 selected SNPs 
revealed no significant difference between group 1 and group 3 as well as compared to the con-
trol group (Table 2). Notably, no significant discrepancy was found for rs7208422 (TMC8 
c.917A>T, p.(Asn306Ile); p=0.15) among the investigated groups. The novel SNP in TMC8 
(c.1766G>A) showed a minor allele frequency (MAF) of A = 0.020/1 in all RTR patients. Overall, 
the MAF in both RTR groups as well as in the control group ranged from 0.014 (rs16970849) to 
0.049 (rs7208422).  
The allele frequency of rs1042522 in TP53 did not significantly differ between the RTR groups 
(group 1 MAF: C=0.219/7, group 3 MAF: C=0.220/11) or in comparison to the control group 
(MAF: C=0.258/51) (Table 1).  
 
Discussion 
Influences of SNPs on cancer development have been debated since their discovery [21,22]. 
TMC6/EVER1 and TMC8/EVER2 are known to be involved in the development of EV. Homozygous 
deleterious alterations in either gene promote the susceptibility of the mutant carrier to β-HPV 
and cSCC [23]. Beta-HPV are discussed to have an impact on cSCC development in RTRs [24-26], 
implicating that SNPs in TMC6/EVER1 and TMC8/EVER2 might consist a risk factor for the differ-
ent susceptibility of RTRs to cSCC. To test this hypothesis we examined RTR starting from seven 
to 42 years after transplantation for SNPs in both TMC/EVER genes. Number of cSCC, age of on-
set, and sex ratio of our study cohort are comparable to previously published data [2,6,27,28].  
Our investigation of TMC6/EVER1 and TMC8/EVER2 in RTR revealed 26 different SNPs causing 
missense or silent mutations or being located in the introns near the exon-intron boundaries. We 
compared the frequency of these SNPs between RTR with severe cSCC affection and RTR without 
any skin cancer. Surprisingly, statistical analyses by the CATT or FT could not identify any SNP 
significantly associated with an increased risk of the development of cSCC in RTR. Neither risk 
analysis by logistic regression revealed any statistical significance. 
Influences of SNPs on both TMC/EVER genes on cSCC development have been investigated re-
cently. First studies examined correlation of a SNP in TMC8/EVER2 (rs7208422), which is located 
in exon 8 of TMC8 and leads to a missense mutation (c.917A>T, p.(Ile306Asp)). This SNP causes a 
reduced binding activity of TMC8 to TRADD (TNFRSF1A-associated via death domain) and leads 
to a less efficient apoptosis activation compared to the wildtype variant [29]. Its variant T was 
homozygously detected in a young HIV positive patient with acquired EV, whereas the HIV posi-
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tive mother was heterozygously detected for the SNP and lacked EV lesions [30]. Two sisters with 
classical EV but without nonsense or frameshift mutation in either of the TMC gene were also 
homozygous for the more rare SNP variant T [31]. Therefore we hypothesized this SNP to influ-
ence the individual risk of cSCC development in combination with immunosuppression. In the 
non-EV population little information is known about the correlation of rs7208422, cSCC devel-
opment, and HPV infection. One study investigating this SNP in the general population reported 
a slightly increased OR (1.7) for individuals with the homozygous T genotype compared to the 
homozygous A genotype [32], a trend we could not confirm in RTR. Our data does not support 
any significant influence of rs7208422 on development of cSCC in the investigated RTR collective. 
Interestingly, among RTR more than 82% of the cSCCs are HPV positive, which is in contrast to 
the general population with a HPV DNA prevalence of only 27% in cSCC [33]. Furthermore, within 
a transplanted but cSCC negative control group more than 60% of carriers of the homozygous 
variant A (rs7208422) or variant G (rs12452890) disclosed a significant association of seropositivi-
ty with β2-HPVs [34]. In compliance with our data no association was recently found between 11 
specific TMC/EVER SNPs and cSCC development in RTRs and cardiac transplant recipients [34]. Of 
note, we have investigated 22 further TMC SNPs in our study, which also do not show any signifi-
cant correlation to cSCC development among RTR. This includes a SNP in TMC6 (rs12449858) 
which has been detected in a family with EV and was suggested to be correlated with EV devel-
opment [35].  
Examination of a further SNP (rs1042522 in the TP53 gene), suggested to be involved in cSCC 
development [20], showed no correlation with cSCC risk in RTR, which is consistent with a single 
report [36] and a recently published meta-analysis [37].  
 
Our pilot study is limited by an unequal distribution of male:female ratio as well as a missing HPV 
analysis of the cSCC. Additionally, it was impossible to evaluate patients’ age at onset of the first 
cSCC because of missing data in the patient record. The presented survey examined few patients 
but all of them were renal transplanted. In correlation with other studies on transplanted pa-
tients we could not detect any correlation between TMC/EVER SNPs and increased risk of cSCC 
development. Possibly, an effect of TMC/EVER SNPs to cSCC development is hidden by other im-
portant influences e.g. the type of HPV infection, age, sex, or skin type. Combined studies on 
large cohorts of the general as well as the RTR population, investigating SNP genotype as well as 
HPV infection and cSCC status, might be necessary to detect a possible influence of TMC/EVER 
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Table 1. Minor allele frequency (MAF) of the analysed SNPs in both RTR groups, our control 
group as well as the NCBI database. SNPs without different alleles in the analysed group are de-
clared as n.d. and such without examination (control group only) as n.a.. Type of used method is 
declared in the last column. 
 
SNP Gene Protein MAF RTR  
group 1 
MAF RTR  
group 3 
MAF controls MAF NCBI type of used 
method 
TMC6/EVER1        
rs2748427 373T>C Trp125Arg C=0.250/8 C=0.167/8 C=0.175/36 C=0.285/621 assay 
rs12449858 457C>T Leu153Phe T=0.125/3 T=0.143/4 T=0.129/27 T=0.140/305 assay 
rs34712518 572G>A Gly191Asp A=0.042/1 n.d. A=0.042/9 A=0.096/209 assay 
rs2613522 1082+5t>c - C=0.375/12 C=0.300/15 C=0.210/45 C=0.417/908 assay 
rs1474865 1083-57c>g - G=0.091/2 G=0.154/4 n.a. G=0.130/284 RFLP (StyI) 
rs2057188 1083-4c>g - G=0.156/5 G=0.100/5 G=0.075/16 G=0.083/180 assay 
rs2748428 1811+25a>g - A=0.437/14 A=0.360/18 G=0.465/94 A=0.275/599 assay 
rs2252496 1812-54t>a - A=0.318/7 A=0.475/19 n.a. A=0.412/897 RFLP (MboI) 
rs79153946 2355-4g>a - A=0.045/1 A=0.036/1 n.a. A=0.008/18 RFLP (Hpy1881) 
rs2253277 *156G>A 3‘ UTR A=0.125/4 A=0.180/9 A=0.083/18 A=0.066/144 assay 
TMC8/EVER2        
rs383603 -239g>c 5‘ UTR G=0.188/6 G=0.180/9 G=0.303/66 G=0.319/695 assay 
rs452483 -187c>t 5‘ UTR T=0.156/5 T=0.100/5 T=0.060/13 T=0.082/178 assay 
rs417780 668+13t>c - C=0.182/4 C=0.179/5 n.a. C=0.276/601 RFLP (AvaII) 
rs7208422 917A>T Asn306Ile T=0.438/14 A=0.420/21 A=0.486/101 A=0.458/997 assay 
rs62079073 988-4g>t - T=0.100/3 T=0.100/5 T=0.084/17 T=0.091/198 RFLP (FauI) 
rs12452890 1107G>A Glu369Glu G=0.406/13 G=0.380/19 G=0.433/91 G=0.438/953 assay 
rs112802399 1024G>T Gly342Trp T=0.045/1 n.d. n.a. T=0.011/23 RFLP (ScrFI) 
rs12449680 1252-52a>g - G=0.344/11 G=0.220/11 G=0.252/52 G=0.373/812 assay 
rs16970849 1349+13g>a  - A=0.100/2 A=0.107/3 A=0.014/3 A=0.160/348 RFLP (Tsp45I) 
rs11651675 1501G>A Val501Ile A=0.083/2 A=0.071/2 A=0.048/10 A=0.019/42 assay 
rs11651650 1533+64c>t - T=0.042/1 n.d. T=0.047/10 T=0.017/36 assay 
rs11651741 1534-23g>a - A=0.042/1 n.d. A=0.057/12 A=0.019/42 assay 
rs11651864 1665-5g>t - T=0.042/1 n.d. T=0.034/7 T=0.019/41 assay 
unknown 
SNP 
1766G>A Arg586His A=0.045/1 n.d. n.a. unknown RFLP (SphI) 
rs7221365 1826+15c>a - C=0.400/12 C=0.375/18 C=0.434/98 C=0.403/877 RFLP (HpaII) 
rs369764 *5t>g 3‘ UTR n.d. n.d. n.d. T=0.002/4 assay 
TP53        







Table 2. Frequency of TMC6/EVER1, TMC8/EVER2 and p53 SNPs analysed in two RTR collectives 
(group 1 and group 3) as well as in the control group. Named are numbers of SNPs and used type 
of test. In case of three different genotypes p-value was calculated by Cochran-Armitage test 
(CATT) and logistic regression (lrpval). In case of only two different genotypes the Fisher test (FT) 
was used. 
SNP Group 1 (%) Group 3 (%) controls test pval lrpval OR (95% CI) 
TMC6        
rs2748427    CATT 0.46 0.46  
TT 11 (68.75) 18 (75.0) 70 (68.0)     
TC 2 (12.5) 4 (16.7) 30 (29.1)    0.89 (0.16 - 4.95) 
CC 3 (18.75) 2 (8.3) 3 (2.9)    2.25 (0.38 - 13.34) 
rs12449858    FT 1 NA  
CC 9 (75.0) 10 (71.4) 79 (75.2)     
CT 3 (25.0) 4 (28.6) 25 (23.8)    0.86 (0.17 - 4.47) 
TT 0 (0) 0 (0) 1 (0.96)    NA 
rs34712518    FT 0.46 NA  
GG 11 (91.7) 14 (100) 97 (91.5)     
GA 1 (8.3) 0 (0) 9 (8.5)    3.78 (0.14 - 101.83) 
AA 0 (0) 0 (0) 0 (0)    NA 
rs2613522    CATT 0.55 0.55  
TT 8 (50.0) 14 (56.0) 65 (60.7)     
TC 4 (25.0) 7 (28.0) 39 (36.5)    1.02 (0.24 - 4.33) 
CC 4 (25.0) 4 (16.0) 3 (2.8)    1.71 (0.36 - 8.09) 
rs1474865    CATT 0.55 0.55  
CC 9 (81.8) 10 (76.9) n.a.     
CG 2 (18.2) 2 (15.4) n.a.    1.11 (0.16 - 7.85) 
GG 0 (0) 1 (7.7) n.a.    0.37 (0.01 - 10.18) 
rs2057188    CATT 0.47 0.47  
CC 11 (68.75) 21 (84.0) 90 (84.9)     
CG 5 (31.25) 3 (12.0) 16 (15.1)    2.94 (0.64 - 13.43) 
GG 0 (0) 1 (4.0) 0 (0)    0.62 (0.02 - 16.56) 
rs2748428    CATT 0.45 0.45  
AA 3 (18.75) 2 (8.0) 27 (26.7)     
AG 8 (50.0) 14 (56.0) 54 (53.5)    0.42 (0.07 - 2.61) 
GG 5 (31.25) 9 (36.0) 20 (19.8)    0.41 (0.06 - 2.86) 
rs2252496    CATT 0.98 0.98  
TT 5 (45.45) 6 (42.9) n.a.     
TA 5 (45.45) 7 (50.0) n.a.    0.87 (0.18 - 4.21) 
AA 1 (9.1) 1 (7.1) n.a.    1.18 (0.09 - 14.87) 
rs79153946    FT 1 NA  
GG 10 (90.9) 13 (92.9) n.a.     
GA 1 (9.1) 1 (7.1) n.a.    1.29 (0.12 - 14.21) 
AA 0 (0) 0 n.a.    NA 
rs2253277    CATT 0.54 0.53  
GG 12 (75.0) 18 (72.0) 90 (83.3)     
GA 4 (25.0) 5 (20.0) 18 (16.7)    1.21 (0.29 - 5.10) 
AA 0 (0) 2 (8.0) 0 (0)    0.30 (0.01 - 6.70) 
TMC8/EVER2        
rs383603    CATT 0.93 0.93  
GG 0 (0) 1 (4.0) 11 (10.1)     
GC 6 (37.5) 7 (28.0) 44 (40.4)    2.6 (0.09 - 75.50) 
CC 10 (62.5) 17 (68.0) 54 (49.5)    1.8 (0.07 - 48.36) 
rs452483    CATT 0.47 0.47  
CC 11 (68.75) 21 (84.0) 96 (88.1)     
CT 5 (31.25) 3 (12.0) 13 (11.9)    2.94 (0.65 - 13.43) 
TT 0 (0) 1 (4.0) 0 (0)    0.62 (0.02 - 16.56) 
rs417780    CATT 0.98 0.98  
tt 7 (63.6) 10 (71.4) n.a.     
15 
 
tc 4 (36.4) 3 (21.4) n.a.    1.8 (0.34 - 9.68) 
cc 0 (0) 1 (7.1) n.a.    0.47 (0.02 - 13.10) 
rs7208422    CATT 0.15 0.15  
AA 3 (18.75) 4 (16.0) 27 (26.0)     
AT 12 (75.0) 13 (52.0) 47 (45.2)    1.19 (0.25 - 5.87) 
TT 1 (6.25) 8 (32.0) 30 (28.8)    0.23 (0.02 - 2.11) 
rs62079073    CATT 1 1  
GG 12 (80.0) 22 (88.0) 84 (83.2)     
GT 3 (20.0) 1 (4.0) 17 (16.8)    4.2 (0.55 - 32.10) 
TT 0 (0) 2 (8.0) 0 (0)    0.36 (0.02 - 8.11) 
rs12452890    CATT 0.81 0.81  
GG 2 (12.5) 4 (16.0) 18 (17.1)     
GA 9 (56.25) 11 (44.0) 55 (52.4)    1.49 (0.25 - 8.72) 
AA 5 (31.25) 10 (40.0) 32 (30.5)    0.94 (0.15 - 6.05) 
rs112802399    FT 0.44 NA  
GG 10 (90.9) 14 (100) n.a.     
GT 1 (9.1) 0 (0) n.a.    4.14 (0.15 – 112.07) 
TT 0 (0) 0 (0) n.a.    NA 
rs12449680    CATT 0.19 0.19  
AA 6 (37.5) 15 (60.0) 58 (56.3)     
AG 9 (56.25) 9 (36.0) 38 (36.9)    2.38 (0.66-8.61) 
GG 1 (6.25) 1 (4.0) 7 (6.8)    2.38 (0.21 - 27.40) 
rs16970849    FT 1 NA  
GG 8 (80.0) 11 (78.6) 105 (97.2)     
GA 2 (20.0) 3 (21.4) 3 (2.8)    0.97 (0.15 - 6.14) 
AA 0 (0) 0 (0) 0 (0)    NA 
rs11651675    FT 1 NA  
GG 10 (83.3) 12 (85.7) 94 (90.4)     
GA 2 (16.7) 2 (14.3) 10 (9.6)    1.19 (0.17 - 8.25) 
AA 0 (0) 0 (0) 0 (0)    NA 
rs11651650    FT 0.46 NA  
CC 11 (91.7) 14 (100) 96 (90.6)     
CT 1 (8.3) 0 (0) 10 (9.4)    3.78 (0.14 - 101.83) 
TT 0 (0) 0 (0) 0 (0)    NA 
rs11651741    FT 0.46 NA  
GG 11 (91.7) 14 (100) 95 (89.7)     
GA 1 (8.3) 0 (0) 10 (9.4)    3.78 (0.14 - 101.83) 
AA 0 (0) 0 (0) 1 (0.9)    NA 
rs11651864    FT 0.46 NA  
GG 11 (91.7) 14 (100) 96 (93.2)     
GT 1 (8.3) 0 (0) 7 (6.8)    3.78 (0.14 - 101.83) 
TT 0 (0) 0 (0) 0 (0)    NA 
unknown SNP    FT 0.44 NA  
GG 10 (90.9) 14 (100) n.a.     
GA 1 (9.1) 0 (0) n.a.    4.14 (0.15 - 112.07) 
AA 0 (0) 0 (0) n.a.    NA 
rs7221365    CATT 0.82 0.82  
CC 2 (13.3) 3 (12.5) 23 (20.4)     
CA 8 (53.3) 12 (50.0) 52 (46.0)    0.95 (0.15 - 6.01) 
AA 5 (33.3) 9 (37.5) 38 (33.6)    0.81 (0.12 - 5.60) 
rs369764    NA NA NA  
TT 0 (0) 0 (0) 0 (0)     
GT 0 (0) 0 (0) 0 (0)    NA 
GG 12 (100) 13 (100) 107 (100)    NA 
TP53        
rs1042522    CATT 0.99 0.99  
CC 2 (12.5) 1 (4.0) 5 (5.1)     
CG 3 (18.8) 9 (36.0) 41 (41.4)    0.22 (0.02 – 2.36) 
GG 11 (68.8) 15 (60.0) 53 (53.5)    0.45 (0.05 – 3.87) 
 
